Mori Yasuharu, Katsumata Kenji, Tokita Hiromi, Kato Fumiaki, Yamamoto Junichi, Tsuchida Akihiko, Aoki Tatsuya
Department of Surgery, Jinwakai General Hospital.
Gan To Kagaku Ryoho. 2007 Sep;34(9):1485-7.
The patient was a 70-year-old man who in November 2000 had undergone pancreatoduodenectomy for a diagnosis of lower bile duct cancer by his previous physician. Left cervical and intra-abdominal lymph node enlargement were detected at 3 years 4 months postoperatively, and a biopsy resulted in a histopathological diagnosis of metastasis by bile duct cancer. Intravenous S-1,120 mg/body, on days 1-14, and CDDP, 20 mg/body, on day 14 was started in April 2004. It was conducted safely on an outpatient basis with no adverse events, and it was possible to achieve survival for 29 months. S-1/CDDP therapy seemed to be capable of serving as a useful treatment for gallbladder and bile duct cancer in the future.
该患者为一名70岁男性,2000年11月其前任医生诊断为低位胆管癌后接受了胰十二指肠切除术。术后3年4个月时发现左颈部和腹腔内淋巴结肿大,活检结果为胆管癌转移的组织病理学诊断。2004年4月开始静脉注射S-1,120mg/体,第1 - 14天用药,顺铂,20mg/体,第14天用药。该治疗在门诊安全进行,无不良事件发生,患者存活了29个月。S-1/顺铂疗法未来似乎有望成为胆囊和胆管癌的有效治疗方法。